According to the Leukemia & Lymphoma Society , Hodgkin’s lymphoma is a highly curable cancer. Survival rates for both NHL and Hodgkin’s lymphoma depend upon how far the cancerous cells have spread and the cancer type. According to the American Cancer Society (ACS), the overall five-year survival rate for NHL patients is 69 percent and the 10-year survival rate is 58 percent. The survival rate for Hodgkin’s lymphoma depends upon its stage. The 5-year survival rate for stage 1 is 90 percent, while the 5-year survival rate for stage 4 is 65 percent.
The prognosis for brain metastases is variable. It depends on the type of primary cancer, the age of the patient, the absence or presence of extracranial metastases, and the number of metastatic sites in the brain.  For patients who do not undergo treatment the average survival is between one and two months.  However, in some patients, such as those with no extracranial metastases, those who are younger than 65, and those with a single site of metastasis in the brain only, prognosis is much better, with median survival rates of up to months.  Because brain metastasis can originate from various different primary cancers, the Karnofsky performance score is used for a more specific prognosis.